




The relative strengths and weaknesses of Kura Oncology Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Kura Oncology Inc compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 12% points. The greatest weakness of Kura Oncology Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 176% points.

The company's Economic Capital Ratio, given in the ranking table, is 34%, being 209% points below the market average of 243%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	0	Assets	9.1
Cost of Goods Sold	0	Liabilities	133
Intangible Assets	0	Expenses	5.9
Liabilities, Current	0.35	Revenues	0
Liabilities, Non-Current	0	Stockholders Equity	-124
Other Assets	9.1	Net Income	-29
Other Compr. Net Income	0	Comprehensive Net Income	-29
Other Expenses	5.9	BaseVar	85
Other Liabilities	133	ECR before LimitedLiability	-421%
Other Net Income	-23	Economic Capital Ratio	34%
Other Revenues	0		
Property and Equipment	0		
Research and Development	0		
Selling, General and Administrative Expense	0		